1st-line treatment of chronic lymphocytic leukemia (CLL) (Binet Stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate. Indolent non-Hodgkin’s lymphoma (iNHL), in patients who have progressed following treatment w/ rituximab containing regimen. Multiple myeloma/MM (Durie-Salmon stage II w/ progress or stage III) after failure to 1st-line treatment in combination w/ prednisone for patients >65 yr who are not eligible for autologous stem-cell transplantation & who have clinical neuropathy at time of diagnosis precluding the use of thalidomide or bortezomib containing treatment.
Dosage/Direction for Use
For IV infusion over 30-60 min. CLL 100 mg/m2 on days 1 & 2 of 4 wk cycles. iNHL 120 mg/m2 on days 1 & 2 of 3 wk cycles. MM 120-150 mg/m2 on days 1 & 2, combined w/ 60 mg/m2 prednisone IV or per os on days 1-4 of 4 wk cycle.
Special Precautions
Interruption of treatment is recommended in case of CTC grade 4 toxicity.
Sign Out
